1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for 'CFS'.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 15th July 2024 is here.
    Dismiss Notice
  3. Welcome! Read the Core Purpose and Values of our forum.
    Dismiss Notice

Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long-term outcomes..., 2022, Eugene Fan et al

Discussion in 'Long Covid research' started by Andy, May 1, 2022.

  1. Andy

    Andy Committee Member

    Messages:
    22,399
    Location:
    Hampshire, UK
    Full title: Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long-term outcomes in COVID-19 patients

    Abstract

    Sustained hypercoagulability and endotheliopathy are present in convalescent COVID-19 patients for up to 4 months from recovery. The hemostatic, endothelial, and inflammatory profiles of 39 recovered COVID-19 patients were evaluated up to 16 months after recovery from COVID-19. These values were compared with a control group of healthy volunteers (n = 124). 39 patients (71.8% males, median age 43 years) were reviewed at a mean of 12.7 ± 3.6 months following recovery. One patient without cardiovascular risk factors had post COVID-19 acute ischaemic limb.

    Elevated D-dimer and Factor VIII levels above normal ranges were noted in 17.9% (7/39) and 48.7% (19/39) of patients respectively, with a higher median D-dimer 0.34 FEU μg/mL (IQR 0.28, 0.46) (p < .001) and Factor VIII 150% (IQR 171, 203) (p = .004), versus controls. Thrombin generation (Thromboscreen) showed a higher median endogenous thrombin potential (ETP) of 1352 nM*min (IQR 1152, 1490) (p = .002) and a higher median peak height of 221.4 nM (IQR 170.2, 280.4) (p = 0.01) and delayed lag time 2.4 min (1.42–2.97) (p = 0.0002) versus controls. Raised vWF:Ag and ICAM-1 levels were observed in 17.9% (7/39) and 7.7% (3/39) of patients respectively, with a higher median VWF:Ag 117% (IQR 86, 154) (p = 0.02) and ICAM-1 54.1 ng/mL (IQR 43.8, 64.1) (p = .004) than controls. IL-6 was noted to be raised in 35.9% (14/39) of patients, with a higher median IL-6 of 1.5 pg/mL (IQR 0.6, 3.0) (p = 0.004) versus controls. Subgroup analysis stratifying patients by COVID-19 severity and COVID-19 vaccination preceding SARS-CoV-2 infection did not show statistically significant differences.

    Hypercoagulability, endothelial dysfunction, and inflammation are still detectable in some patients approximately 1 year after recovery from COVID-19.

    Open access, https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.26575
     
    Andy, May 1, 2022
    #1
    Jacob Richter, Michelle, Lilas and 5 others like this.
  2. Andy

    Andy Committee Member

    Messages:
    22,399
    Location:
    Hampshire, UK
    Andy, May 1, 2022
    #2
    merylg, Hutan and Peter Trewhitt like this.
  3. Hutan

    Hutan Moderator Staff Member

    Messages:
    27,993
    Location:
    Aotearoa New Zealand
    Interesting study at around the one year mark.

    This is a bit scary:
    There are % errors in Table 1.


    Figure 1: Box and whisker plots of statistically significant hemostatic, endothelial and inflammatory parameters

    Screen Shot 2022-05-01 at 9.36.22 pm.png

    Also:
    Some questions from our point of view are,
    do these results correlate with Long Covid symptoms?
    how unique are these results to post-Covid-19, i.e. do people with ME/CFS following other illnesses show these results too?
     
    Hutan, May 1, 2022
    #3
    Michelle, alktipping, merylg and 4 others like this.

Share This Page